218 related articles for article (PubMed ID: 27896711)
1. Using EQ-5D-3L and OAB-5D to assess changes in the health-related quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Hakimi Z; Herdman M; Pavesi M; Devlin N; Nazir J; Hoyle C; Odeyemi IA
Qual Life Res; 2017 May; 26(5):1187-1195. PubMed ID: 27896711
[TBL] [Abstract][Full Text] [Related]
2. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Nazir J; Heemstra L; van Engen A; Hakimi Z; Ivanescu C
BMC Urol; 2015 May; 15():41. PubMed ID: 25956727
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
5. Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.
Rees J; Foley S; Huang M; Rosa Arias J; Skoumal R; Walters C; Yavuz Y; De Wachter S
Neurourol Urodyn; 2019 Mar; 38(3):981-989. PubMed ID: 30801782
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
[TBL] [Abstract][Full Text] [Related]
7. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
8. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
[TBL] [Abstract][Full Text] [Related]
9. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.
Desroziers K; Aballéa S; Maman K; Nazir J; Odeyemi I; Hakimi Z
Health Qual Life Outcomes; 2013 Nov; 11():200. PubMed ID: 24246044
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK.
Trueman P; Hood SC; Nayak US; Mrazek MF
BJU Int; 1999 Mar; 83(4):410-5. PubMed ID: 10210562
[TBL] [Abstract][Full Text] [Related]
11. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in adult males with lower urinary tract symptoms.
Kim SK; Kim KH; Kim SH; Yoo SJ; Jeong YW
Qual Life Res; 2019 Sep; 28(9):2419-2428. PubMed ID: 31087248
[TBL] [Abstract][Full Text] [Related]
13. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.
Fourcade RO; Lacoin F; Rouprêt M; Slama A; Le Fur C; Michel E; Sitbon A; Cotté FE
World J Urol; 2012 Jun; 30(3):419-26. PubMed ID: 21892656
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
16. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
17. Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Mathias SD; Crosby RD; Nazir J; Klaver M; Drogendijk T; Hakimi Z; Odeyemi IA
Value Health; 2014 Dec; 17(8):823-9. PubMed ID: 25498777
[TBL] [Abstract][Full Text] [Related]
18. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
[TBL] [Abstract][Full Text] [Related]
19. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.
Drake MJ; Oelke M; Snijder R; Klaver M; Traudtner K; van Charldorp K; Bongaerts D; Van Kerrebroeck P
PLoS One; 2017; 12(2):e0170726. PubMed ID: 28166296
[TBL] [Abstract][Full Text] [Related]
20. [Cost-effectiveness model of a fixed dose combination of solifenacin and tamsulosin for the treatment of LUTS associated with BPH with inadequate response to monotherapy.].
Alcántara A; Cózar JM; Errando C; Rubio-Rodríguez D; Rubio-Rodríguez D; Rubio-Terrés C; Mora AM; Duran A
Arch Esp Urol; 2018 Sep; 71(7):595-606. PubMed ID: 30198851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
